

**Ganga Pharmaceuticals Limited**

CIN: L99999MH1989PLC053392

Regd. Office: Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar - 401305  
Phone: 9834613142 | Website: [www.ayurvedganga.com](http://www.ayurvedganga.com) | Email: [ayurvedganga@gmail.com](mailto:ayurvedganga@gmail.com).

July 25, 2025

To,  
Corporate Relationship Department,  
BSE Ltd  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai- 400001

Scrip code: **539680**

**Subject: Submission of Share Reconciliation Audit Report under Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on June 30, 2025.**

Dear Sir/Madam,

Pursuant to Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed herewith the Share Reconciliation Audit Report for the quarter ended on June 30, 2025.

Kindly take same on record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully,  
**For Ganga Pharmaceuticals Limited**

**Bharat Sharma**  
**Managing Director**  
DIN: 00077026  
Email ID: [bharat.sharma@gangapharma.in](mailto:bharat.sharma@gangapharma.in).

**Encl: As above**

**The Board of Directors**

**Ganga Pharmaceuticals Limited**

[CIN: L99999MH1989PLC053392]

Gangatat Dhanvantri Marg, Gopcharpada,  
Virar (East), Palghar - 401305

**RECONCILIATION OF SHARE CAPITAL AUDIT REPORT**

We have examined the Register of Members, beneficiary details furnished by the Depositories and other relevant books, records, documents and register maintained by **Ganga Pharmaceuticals Limited** (hereinafter referred to as 'the Company') and its Registrars and Transfer Agents i.e. **KFin Technologies Limited, Hyderabad** for the purpose of issuing this certificate in accordance with Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 as per SEBI notification dated October 03, 2018.

In our opinion and to the best of our information and according to the explanations given to us and based on such verification and examination as considered necessary, the Reconciliation of Share Capital Audit Report for the quarter ended on June 30, 2025 enclosed herewith.

**For R M Mimani & Associates LLP**

**[Company Secretaries]**

[Firm Registration No. L2015MH008300]

MANOJ  
KUMAR  
MIMANI

Digitally signed by  
MANOJ KUMAR MIMANI  
Date: 2025.07.11  
19:18:47 +05'30'

**Manoj Mimani**

**Partner**

ACS No.: 17083

C.P. No.: 11601

PR No.: 1065/2021

UDIN: A017083G000761640

Place: Mumbai

Dated: July 11, 2025

# R M MIMANI & ASSOCIATES LLP

## COMPANY SECRETARIES

### ANNEXURE TO RECONCILIATION OF SHARE CAPITAL AUDIT REPORT OF GANGA PHARMACEUTICALS LIMITED FOR THE QUARTER ENDED ON JUNE 30, 2025

1	For Quarter ended	June 30, 2025	
2	ISIN	INE615T01017	
3	Face Value	Rs.10/-	
4	Name of the Company	<b>Ganga Pharmaceuticals Limited</b>	
5	Registered Office Address	Gangatat Dhanvantri Marg, Gopcharpada Virar (East), Palghar - 401305	
6	Correspondence Address	Same as Above	
7	Telephone & Fax Nos.	Tel No. : 0250 - 6098333/444 /666 / 502, Fax No.:0250 - 2528602	
8	Email Address	<a href="mailto:ayurvedganga@gmail.com">ayurvedganga@gmail.com</a>	
9	Names of the Stock Exchanges where the Company's securities are listed:	BSE Limited - SME Segment	
		Number of Shares	% of total issued Capital
10	Issued capital	48,36,500	100.00
11	Listed Capital - BSE Limited	48,36,500	100.00
12	Held in dematerialized form in CDSL	36,54,440	75.56
13	Held in dematerialized form in NSDL	9,91,210	20.49
14	Physical	1,90,850	3.95
15	Total No. of shares (12+13+14)	48,36,500	100.00

16. Reason for difference if any, between (10 &11) & (10 &15) & (11 & 15) : NA

17. Certifying the details of changes in share capital during the quarter under consideration as per Table given below:

Particulars	No. of Shares	Applied/ Not Applied For Listing	Listed On stock exchanges (Specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In principal approval pending for SE (Specify names)
Nil						

\*\* Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify);

18. Register of Members is updated (Yes/No) : **Yes**  
If not, updated upto which dates : **Not Applicable**

19. Reference of previous quarter with regard to excess dematerialized shares, if any : **Nil**

20. Has the company resolved the matter mentioned in point no.19 above in the current quarter? if yes, reason why? : **Not Applicable**

MANOJ  
KUMAR  
MIMANI

Digitally signed  
by MANOJ  
KUMAR MIMANI  
Date: 2025.07.11  
19:19:04 +05'30'

# R M MIMANI & ASSOCIATES LLP

## COMPANY SECRETARIES

21. Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of request pending beyond 21 days with the reason for delay:

Total no. of demat request	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	Nil	Nil	Not applicable
Pending for more than 21 days	Nil	Nil	Not applicable

22.	Name, Telephone & Fax Nos. of the Compliance Officer of the Co.	NA **
23.	Name, Address Telephone & Fax No., Regn. No. of the Auditor.	Manoj Mimani R M Mimani & Associates LLP A/101, Excellency, Old Raviraj Complex, Jesal Park, Bhayander (E), Thane- 401 105; Tel: 9136702774 CP No. 11601
24.	Appointment of common agency for share registry work. (if yes, name & address)	KFin Technologies Limited Selenium Tower B, Plot No. 31& 32, Financial District, Nanakramguda, Hyderabad - 500032; Tel No.- 040 - 67162222; Fax: 040 - 23431551

25. Any other details that the auditor may like to provide (e.g., BIFR company, delisting from SE, company changed its name etc.):-

\*\* Ms. Priti Bhaiya, Company Secretary and Compliance Officer of the Company has resigned with effect from April 22, 2025

**For R M Mimani & Associates LLP**  
**[Company Secretaries]**  
[Firm Registration No. L2015MH008300]

MANOJ KUMAR MIMANI  
Digitally signed by  
MANOJ KUMAR MIMANI  
Date: 2025.07.11 19:19:20  
+05'30'

**Manoj Mimani**  
**Partner**

ACS No.: 17083

C.P. No.: 11601

PR No.: 1065/2021

UDIN: A017083G000761640

Place: Mumbai

Dated: July 11, 2025